Amylyx Pharmaceuticals, Inc. AMLX Total Cost of Revenue
Discontinued — last reported Q4 '25
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Amylyx Pharmaceuticals, Inc.’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amylyx Pharmaceuticals, Inc.'s total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amylyx Pharmaceuticals, Inc.'s total cost of revenue?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported total cost of revenue of $0 in Q4 2025.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s total cost of revenue?
- Over 2 years (2023 to 2025), Amylyx Pharmaceuticals, Inc.'s total cost of revenue has grown at a -100.0% compound annual growth rate (CAGR), from $25.44M to $0.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.